URGENT:ALL BLOOD TYPES ARE NEEDEDGIVE TODAY

Partner and Licensing Opportunities

New York Blood Center Enterprises (NYBCe)—one of the United States' leading suppliers of blood products and services—boasts world-class research that has paved the way for new blood-related products, techniques and therapies resulting in numerous landmark patents and licenses.

We are your gateway to technology licenses, sponsored research, collaborations and venture creations across the entire NYBC Enterprise. Below are NYBCe's current partnering opportunities. 


Heparin-Induced Thrombocytopenia and Thrombosis (HITT): First-in-class therapeutic candidate for acute non-malignant hemtaologic disorder

Under the leadership of Vice President and Chief Medical Officer, Bruce Sachais, MD, PhD, the Platelet Research Laboratory's focus is on improved diagnosis and novel therapeutics for heparin-induced thrombocytopenia/thrombosis (HITT). Platelet factor 4 antagonists (PF4As) represent a novel approach to the treatment and prevention of HITT, and show tremendous potential for this disorder.

Current drugs (general antithrombotics) used for treating HIT/HITT are generally not very effective and have safety issues regarding bleeding. Lead candidate-FC-7259directly addresses the pathophysiology of HITT with little or no increased risk of bleeding and has good drug properties for IV administration.

NYBC is seeking partnership(s) to take this lead PF4A ( FC-7259) to IND.  Learn more about our Small Molecule Antagonists of PF4 for the Treatment and Prevention of HITT by clicking the button below.

Access PF4a Lead Candidate Teaser

Dr Sachais Interviews on HITT Research


Novel Coronavirus Therapeutic Portfolio: Addressing the Significant Unmet Need for Treating Symptomatic Disease and Risks Associated with Vaccine Hesitancy

In response to the global COVID-19 pandemic, specifically, in viral immunology and infectious diseases, NYBCe’s research and development continues to treat the current pandemic while focusing on ground breaking research to prevent future outbreaks, as well as treat those with early symptomatology. Under the leadership of Asim K. Debnath, PhD, Head of Molecular Modeling and Drug Design, NYBCe's focus is on preventing future outbreaks, as well as treat those with early symptomatology by developing two assets addressing the global COVID-19 pandemic including: 

  • Proprietary antiviral therapeutic peptides
  • Novel small molecule fusion inhibitors

NYBCe has a broad portfolio of therapeutic agents which have preliminary data suggesting potential to be leaders in the global market for effective and accessible COVID-19 therapeutics.

NYBCe is seeking a development and commercialization partner(s) to advance its antiviral assets into clinical candidates through the regulatory and marketing approval process on a global or regional basis. Learn more about our small molecule fusion inhibitors by clicking the button below. 

Access NYBCe's COVID Antiviral Candidate Teaser

DR. DEBNATH Interviews on COVID-19 Research


Connect with Us

Our experienced team, led by Executive Vice President and Chief Financial and Business Officer, Jay Mohr, has deep expertise in basic research, business development, M&A and complex operations and integration.

CONTACT